Need Help?

To reveal the spectrum of gene mutations in grade II/III gliomas, whole exome sequencing of 52 samples including 4 multi-regional and 10 multi-time points sampling cases and 291 SNP-array were performed.

To reveal the spectrum of gene mutations in grade II/III gliomas, whole exome sequencing of 52 samples including 4 multi-regional and 10 multi-time points sampling cases and 291 SNP-array were performed. Our analysis revealed high degrees of temporal/spatial heterogeneity generated during tumor expansion and relapse.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001213 Illumina HiSeq 2000 5
EGAD00010000682 762
EGAD00010000684 3
EGAD00010000686 5
EGAD00010000688 119
Publications Citations
Clonal evolution of glioblastoma under therapy.
Nat Genet 48: 2016 768-776
402
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities.
Nat Cancer 2: 2021 141-156
126
Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.
Cancer Res 81: 2021 4861-4873
5
Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas.
Cell Rep Med 4: 2023 101082
1
Differential expression of the circadian clock network correlates with tumour progression in gliomas.
BMC Med Genomics 16: 2023 154
1